EN DE
STOCK COMPARISON

Senores Pharmaceuticals L vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Senores Pharmaceuticals L (SENORES) and Eli Lilly and (LLY) compare, as of Aug 18, 2026.

As of Aug 18, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Senores Pharmaceuticals L trades at ₹1,546 versus a fair value of ₹375 (-76%), while Eli Lilly and trades at $1,183 versus $389 (-67%).
Senores Pharmaceuticals L
SENORES.NSE · INR · Healthcare
-76%
upside to fair value
overvalued
Price₹1,546
Fair Value₹375
Quality43/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,183
Fair Value$389
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Senores Pharmaceuticals LEli Lilly and
Valuation
58.7×P/E (TTM)42.2×
10.06×P/S (TTM)14.67×
6.82×P/B39.94×
38.7×EV/EBITDA30.2×
PEG1.54×
Dividend yield0.5%
Dividend per share$6.23
Profitability
18%Net margin35%
22%Operating margin49%
14%Return on equity107%
6%Return on assets21%
Growth
53%Revenue growth (YoY)56%
161.6%Avg. growth/yr (3Y)31.7%
Avg. growth/yr (5Y)21.6%
Balance & size
0.21×Debt / equity1.54×
$668MMarket cap$1.1T
expensiveGrowth qualitymixed

Eli Lilly and leads: 4 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Senores Pharmaceuticals Lof which business quality 43 · market factors 84 Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
49
85
Quality GrowthAre margins and returns improving?
75
86
CashflowEarnings quality: real cash, not paper profit
11
51
Fin. StrengthBalance sheet, leverage, solvency risk
65
53
InvestmentDisciplined investing over empire-building
0
15
Low VolatilityCalm price path (market factor)
45
77
MomentumPrice trend over the last 3–12 months (market factor)
100
76
52W MomentumDistance to the 52-week high (market factor)
100
95
Net IssuanceBuybacks instead of dilution
50
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Senores Pharmaceuticals L

Earnings-Based₹877
Multiples₹450
Asset-Based₹136
Economic Profit₹222
Growth Earnings₹1,164

14 of 14 models see the stock below the current price.

Eli Lilly and

DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Senores Pharmaceuticals L
Bear ₹271Fair Value ₹375Bull ₹483
₹1,546 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,183 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Senores Pharmaceuticals L · Healthcare

Quality score43 · below median
Fair value upside-76% · bottom 25%

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-67% · bottom 25%

Bottom line

As of Aug 18, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Senores Pharmaceuticals L trades at ₹1,546 versus a fair value of ₹375 (-76%), while Eli Lilly and trades at $1,183 versus $389 (-67%).

Eli Lilly and has the higher quality score (69/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.